Karki P, Koirala S, Parija S C, Hansdak S G, Das M L
Department of Medicine and Microbiology, BP Koirala, Institute of Health Sciences, Dharan, Nepal.
Southeast Asian J Trop Med Public Health. 1998 Mar;29(1):154-8.
Twenty-seven cases of Kala-azar were treated with sodium stibogluconate at a dose of 20 mg/kg/day for 20 days (group A) and an equal number of cases were treated with the same dose but for a longer duration of 30 days (group B). Clinical and laboratory evaluation of these cases were carried out before and after therapy, during a follow up of cases every month, upto 6 months. Renal and liver function tests and electrocardiography were carried out of monitor any toxic effect of the drug during therapy. The cure rates of patients were 77.78% and 92.59% in group A and B cases respectively. Six and two patients in group A and B respectively were unresponsive to the treatment and showed relapse. Results of the study show that treatment of cases of Kala-azar with sodium stibogluconate in a dosage of 20 mg/kg/day for a longer period of 30 days is effective with a higher cure rate and minimum side effects, for treatment of cases of Kala-azar in this eastern part of Nepal, endemic for the disease.
27例黑热病患者接受葡萄糖酸锑钠治疗，剂量为20mg/kg/天，持续20天（A组），另有相同数量的病例接受相同剂量但疗程更长的30天治疗（B组）。在治疗前后、每月随访直至6个月期间，对这些病例进行了临床和实验室评估。在治疗期间进行了肾功能和肝功能检查以及心电图检查，以监测药物的任何毒性作用。A组和B组患者的治愈率分别为77.78%和92.59%。A组和B组分别有6例和2例患者对治疗无反应并出现复发。研究结果表明，在尼泊尔东部这种疾病的流行地区，用葡萄糖酸锑钠以20mg/kg/天的剂量治疗30天的较长疗程对黑热病病例有效，治愈率更高且副作用最小。
